Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2018 Photo Charl Devenish
Mountain research Maloti-Drakensberg
Tucked in the foothills of the Maloti-Drakensberg Mountains is the Qwaqwa Campus of the University of the Free State (UFS), the home of the Afromontane Research Unit (ARU).

Mountains and highlands have always played an important role in the history of mankind. They produce economically essential goods and services (such as fresh water), host unique biodiversity, and offer unique recreational and tourism opportunities. Mountains are also a place for spiritual sanctuaries and are often used for journeys of self-reflection through pilgrimage.

In addition to these ‘feel good’ benefits, mountains are hazardous areas for communities and infrastructure and are vulnerable to natural disasters. Mountainous areas are also often natural borders defining geopolitical entities, but in the process splitting and marginalising communities, creating economic shadow zones and sometimes becoming highly militarised areas. 

“Southern African mountains provide enormous opportunities for holistic research as social-ecological systems, with some of the most interesting and least academically explored environments on Earth,” said Dr Vincent Clark, Director: Afromontane Research Unit (ARU) on the UFS Qwaqwa Campus

The Afromontane Research Unit
The Qwaqwa Campus of the University of the Free State (UFS) is the home of the ARU, a multidisciplinary flagship group addressing the largely under-researched mountainous landscapes of southern Africa. 

Research in the ARU is promoted around three broad themes to foster inter- and multidisciplinary discourse: (1) conservation and sustainable use of Afromontane biodiversity; (2) sustainable futures for the people of the Afromontane; and (3) living and doing business in the Afromontane –  with the intention of creating a sustainability science hub to bring the three themes into the ambit of solution-oriented transdisciplinary research, centred in the sustainable development goals and sustainability research in general. 

Continental leader
To achieve its vision of becoming a continental leader in African mountain research, the ARU is positioning itself as a mountain-knowledge generator and interchange by developing key relationships locally and internationally. The most valuable local partnership is with the South African Environmental Observation Network (SAEON), with which the ARU will be sharing a Research Chair. 

The Chair will contain strong expertise in the Social Sciences to complement the existing strong Natural Science element in both the ARU and SAEON. The Sustainability Science component is being built through inter alia a mutually-reinforcing relationship with the University of Tokyo and United Nations University, Tokyo. 

The future
“In tandem with robust collaborations to achieve its goals, the ARU provides an envious capacity-building programme for its early career campus academics, postdoctoral and postgraduate students,” said Dr Clark. 

The scale of influence of the ARU is prioritised as ‘back yard first’, namely solution-oriented research that benefits Phuthaditjhaba, Qwaqwa, Golden Gate Highlands National Park and Royal Natal National Park. Thereafter, the ARU seeks to facilitate research that encourages the sustainable development of the Maloti-Drakensberg as a unique social-ecological system in Africa, and from there facilitate research in the intellectual vacuum that is the southern African mountains. With time, the ARU aims to take the intellectual lead as an Africa-based leader in African mountain research. The success of this will depend on how carefully the development of human infrastructure can be balanced with that of the myriad opportunities presented.”

With a diverse and motivated team, situated in one of the most attractive environments in Africa, the ARU is here to change the way we think about African mountains and what they mean for us all. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept